Literature DB >> 1354355

Carboxyl-terminal deletion and point mutations decrease the transforming potential of the activated rat neu oncogene product.

Y Mikami1, J G Davis, K Dobashi, W C Dougall, J N Myers, V I Brown, M I Greene.   

Abstract

The rat neu oncogene encodes a constitutively activated growth factor receptor/transmembrane tyrosine kinase, p185Tneu, that is structurally similar to yet distinct from the epidermal growth factor receptor. To explore the role of the carboxyl-terminal region and of putative autophosphorylation sites in regulating the activity of the rat p185Tneu (T, transforming) protein, we used site-directed mutagenesis to generate a p185Tneu mutant in which a putative tyrosine autophosphorylation site (residue 1253) at the extreme carboxyl terminus was replaced by a phenylalanine residue and a mutant in which the carboxyl-terminal 122 amino acids were deleted. These proteins were expressed in NIH 3T3 cells at comparable levels and exhibited similar autophosphorylation activity, exogenous substrate phosphorylation ability, oligomerization levels, and responsiveness to a partially purified neu-activating factor. However, the mutant p185Tneu proteins displayed a decreased transforming capacity both in vitro and in vivo. This analysis demonstrated that the carboxyl-terminal domain and at least one putative tyrosine autophosphorylation site of p185Tneu play a role in positively regulating the cell growth-regulating properties of the neu protein.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1354355      PMCID: PMC49704          DOI: 10.1073/pnas.89.16.7335

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

Review 1.  Signal transduction by receptors with tyrosine kinase activity.

Authors:  A Ullrich; J Schlessinger
Journal:  Cell       Date:  1990-04-20       Impact factor: 41.582

2.  Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein.

Authors:  D B Weiner; Y Kokai; T Wada; J A Cohen; W V Williams; M I Greene
Journal:  Oncogene       Date:  1989-10       Impact factor: 9.867

3.  Experimental approaches to hypothetical hormones: detection of a candidate ligand of the neu protooncogene.

Authors:  Y Yarden; R A Weinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

4.  Characterization of a neu/c-erbB-2 protein-specific activating factor.

Authors:  K Dobashi; J G Davis; Y Mikami; J K Freeman; J Hamuro; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

5.  The transforming potential of the c-erbB-2 protein is regulated by its autophosphorylation at the carboxyl-terminal domain.

Authors:  T Akiyama; S Matsuda; Y Namba; T Saito; K Toyoshima; T Yamamoto
Journal:  Mol Cell Biol       Date:  1991-02       Impact factor: 4.272

6.  The carboxy-terminal domains of erbB-2 and epidermal growth factor receptor exert different regulatory effects on intrinsic receptor tyrosine kinase function and transforming activity.

Authors:  P P Di Fiore; O Segatto; F Lonardo; F Fazioli; J H Pierce; S A Aaronson
Journal:  Mol Cell Biol       Date:  1990-06       Impact factor: 4.272

7.  All autophosphorylation sites of epidermal growth factor (EGF) receptor and HER2/neu are located in their carboxyl-terminal tails. Identification of a novel site in EGF receptor.

Authors:  B L Margolis; I Lax; R Kris; M Dombalagian; A M Honegger; R Howk; D Givol; A Ullrich; J Schlessinger
Journal:  J Biol Chem       Date:  1989-06-25       Impact factor: 5.157

8.  Autophosphorylation sites on the epidermal growth factor receptor.

Authors:  J Downward; P Parker; M D Waterfield
Journal:  Nature       Date:  1984 Oct 4-10       Impact factor: 49.962

9.  The role of autophosphorylation in modulation of erbB-2 transforming function.

Authors:  O Segatto; F Lonardo; J H Pierce; D P Bottaro; P P Di Fiore
Journal:  New Biol       Date:  1990-02

10.  Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells.

Authors:  P P Di Fiore; J H Pierce; T P Fleming; R Hazan; A Ullrich; C R King; J Schlessinger; S A Aaronson
Journal:  Cell       Date:  1987-12-24       Impact factor: 41.582

View more
  3 in total

1.  Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation.

Authors:  D L Dankort; Z Wang; V Blackmore; M F Moran; W J Muller
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

2.  Human prostatic acid phosphatase, an authentic tyrosine phosphatase, dephosphorylates ErbB-2 and regulates prostate cancer cell growth.

Authors:  Tsai-Der Chuang; Siu-Ju Chen; Fen-Fen Lin; Suresh Veeramani; Satyendra Kumar; Surinder K Batra; Yaping Tu; Ming-Fong Lin
Journal:  J Biol Chem       Date:  2010-05-24       Impact factor: 5.157

3.  Activation of ErbB2 during wallerian degeneration of sciatic nerve.

Authors:  Y K Kwon; A Bhattacharyya; J A Alberta; W V Giannobile; K Cheon; C D Stiles; S L Pomeroy
Journal:  J Neurosci       Date:  1997-11-01       Impact factor: 6.167

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.